TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Jaguar Animal Health ( (JAGX) ) is now available.
On November 12, 2025, Jaguar Health, Inc. entered into a note purchase agreement with Streeterville Capital, LLC, issuing a secured promissory note worth $10,810,000. The agreement includes an original issue discount and legal fees, with funds allocated to a newly formed subsidiary, JAGX Holdings, LLC. The note carries an 8% annual interest rate, with a 36-month maturity period, and includes provisions for mandatory prepayments and redemption rights. The company’s obligations are secured by various agreements, and certain covenants restrict Jaguar Health’s financial activities, ensuring compliance with the lender’s terms.
The most recent analyst rating on (JAGX) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Jaguar Animal Health stock, see the JAGX Stock Forecast page.
Spark’s Take on JAGX Stock
According to Spark, TipRanks’ AI Analyst, JAGX is a Neutral.
Jaguar Animal Health’s overall stock score is primarily impacted by its poor financial performance, characterized by high leverage and consistent losses. While there is some positive sentiment from recent earnings and clinical advancements, the technical indicators and valuation metrics remain weak, contributing to a low overall score.
To see Spark’s full report on JAGX stock, click here.
More about Jaguar Animal Health
Average Trading Volume: 143,831
Technical Sentiment Signal: Sell
Current Market Cap: $6.49M
See more data about JAGX stock on TipRanks’ Stock Analysis page.